bluuebunny/crossref_metadata_2025_split huggingface dataset:
Assessment of Left Ventricular Diastolic Function in Patients with Diffuse LargeB-cell Lymphoma after Anthracycline Chemotherapy by using Vector FlowMapping
Authors: Yang Kun , Hu Jia , Yuan Xinchun , Xiahou Yu , Ren Ping 
Published: June 2024

Background:
Patients with diffuse large B-cell lymphoma (DLBCL) often experience a poor prognosis due to cardiac damage induced by anthracycline
chemotherapy, with left ventricular diastolic dysfunction manifesting early. Vector Flow Mapping (VFM) is a novel technology, and its
effectiveness in detecting left ventricular diastolic dysfunction following anthracycline chemotherapy remains unverified.

Objects:
This study evaluates left ventricular diastolic function in DLBCL patients after anthracycline chemotherapy using vector flow mapping (VFM).

Materials and Methods:
We prospectively enrolled 54 DLBCL patients who had undergone anthracycline chemotherapy (receiving a minimum of 4 cycles) as the case
group and 54 age- and sex-matched individuals as controls. VFM assessments were conducted in the case group pre-chemotherapy (T0), post-4
chemotherapy cycles (T4), and in the control group. Measurements included basal, middle, and apical segment energy loss (ELb, ELm, ELa) and
intraventricular pressure differences (IVPDb, IVPDm, IVPDa) across four diastolic phases: isovolumic relaxation (D1), rapid filling (D2), slow
filling (D3), and atrial contraction (D4).

Results:
When comparing parameters between the control and case groups at T0, no significant differences were observed in general data, conventional
ultrasound parameters, and VFM parameters (all P > 0.05). From T0 to T4, ELa significantly increased throughout the diastole cycle (all P < 0.05);
ELm increased only during D4 (all P < 0.05); and ELb increased during D1, D2, and D4 (all P < 0.05). All IVPD measurements (IVPDa, IVPDm,
IVPDb) increased during D1 and D4 (all P < 0.05) but decreased during D2 and D3 (all P < 0.05). Significant positive correlations were identified
between ELa-D4, IVPDa-D4, and parameters A, e’, E/e,’ and LAVI (all r > 0.5, all P < 0.001). Negative correlations were noted with E/A for ELa-
D4 IVPDa-D4 (all r < -0.5, all P < 0.001). Positive correlations were observed for IVPDa-D1, IVPDa-D2 with E, E/e’, and LAVI (0.3<r<0.5, all P<0.001).

Conclusion:
VFM parameters demonstrate a certain correlation with conventional diastolic function parameters and show promise in assessing left ventricular
diastolic function. Furthermore, VFM parameters exhibit greater sensitivity to early diastolic function changes, suggesting that VFM could be a
novel method for evaluating differences in left ventricular diastolic function in DLBCL patients before and after chemotherapy.
Development and Validation of New HPLC Method for the Determination of Imidazolidinyl Urea in Topical Formulation
Authors: Kızılçay Gamze Ergin , Toker Sıdıka Ertürk , Matur Dilek 
Published: June 2024

Introduction:
In this study, a new, simple, selective, and fast liquid chromatographic
method has been developed and validated for the determination of imidazolidinyl urea used as an
anti-microbial agent in topical formulation.

Methods:
The developed HPLC method using a diode array detector for the determination of imidazolidinyl
urea was applied to the topical formulation. Imidazolidinyl urea in the sample was analyzed
in the cyano column (250 x 4,6 mm, 5 μm i.d.) under chromatographic conditions, where
the flow rate was determined as 1.0 mL/min. The column oven was 40.0°C, and imidazolidinyl
urea was detected at 210 nm. Isocratic application of acetonitrile-water (25:75, v/v) was used as
the mobile phase system. The validation of the developed method was performed according to the
International Conference on Harmonisation guidelines Q2 (R1).

Results:
The linearity range of the imidazolidinyl urea was 0.050-0.150 mg/mL, and the limits of
detection and quantification were calculated to be 62.5x10-6 mg/mL and 125x10-6 mg/mL, respectively.
Assay recovery and precision of imidazolidinyl urea from topical formulation at 0.050,
0.100, and 0.125 mg/mL concentrations were evaluated. The mean recoveries for imidazolidinyl
urea in the topical formulation were calculated as 98.857-104.560%.

Conclusion:
The validated method was successfully applied to the determination of imidazolidinyl
urea in a topical formulation. The proposed method is reproducible and reliable and can be
used safely for routine analysis.
Association Between Gallstone Disease and Risk of Mortality of
Cardiovascular Disease and Cancer: A Systematic Review and
Meta-Analysis
Authors: Rahimi Rasoul , Masoumi Shahab , Badali Ahmadreza , jafari Negar , Heidari-Soureshjani Saeid , Sherwin Catherine M.T. 
Published: June 2024

Background:
Gallstone disease (GD) is increasing in the world and has various complications.

Objective:
This study aims to examine the relationship between GD and the risk of mortality from
cardiovascular disease (CVD) and cancer using a systematic review and meta-analysis approach.

Methods:
A comprehensive and systematic search was done in various databases, such as Web of
Science (WOS), Scopus, MEDLINE/PubMed, Cochrane, and Embase. The search included
studies published from 1980 to December 2023. Heterogeneity was assessed using Chi-square, I2,
and forest plots, while publication bias was evaluated through Begg's and Egger's tests. All analyses
were performed using Stata 15, with statistical significance set at p <0.05.

Results:
A pooled analysis of five studies involving 161,671 participants demonstrated that individuals
with GD had a significantly higher risk of mortality from CVD (RR 1.29, 95% CI:
1.11-1.50, p <0.001). Importantly, no evidence of publication bias was found based on the results
of Begg's test (p =0.806) and Egger's test (p =0.138). Furthermore, the pooled analysis of seven
studies, encompassing a total of 562,625 participants, indicated an increased risk of cancer mortality
among individuals with GD (RR 1.45, 95% CI: 1.16-1.82, p <0.001). Similarly, no publication
bias was detected through Begg's test (p =0.133) and Egger's test (p =0.089).

Conclusion:
In this study, the evidence of a significant association between GD and an elevated
risk of mortality from CVD and canceris provided. These findings suggest that implementing targeted
interventions for individuals with gallstone disease could reduce mortality rates among these
patients.
An In vitro Study on the Antibacterial Effect of a Combined Photodynamic and Sonodynamic Therapy Using IR780 Iodide-loaded Mesoporous Silica Nanoparticles Against P. aeruginosa and Multi-Drug Resistant P. aeruginosa
Authors: Alagha Heba Z. , Gülsoy Murat 
Published: June 2024

Background:
The aim of this study was to investigate the antimicrobial photodynamic,
sonodynamic, and combined photodynamic and sonodynamic potentials of IR780 iodide
loaded mesoporous silica nanoparticles against gram-negative Pseudomonas aeruginosa
(P. aeruginosa) and multi drug resistant Pseudomonas aeruginosa (MDR P. aeruginosa).

Methods:
IR780 iodide loaded mesoporous silica nanoparticles were synthesized, and their
antimicrobial photodynamic and sonodynamic potentials against one P. aeruginosa strain,
and one MDR P. aeruginosa strain were investigated. Laser irradiation was achieved via a
785 nm diode laser (500 mW/cm2, 5 min). Ultrasound irradiation was achieved via a 1-MHz
ultrasound unit (1.5 W/cm2, 50% duty cycle, 3 min). Viable bacterial cells were counted by
serial dilution method. Data were analyzed by ANOVA followed by Tukey's test (p ≤ 0.05).

Results:
The results revealed that for P. aeruginosa, the combined photodynamic therapy
(PDT) and sonodynamic therapy (SDT) showed a 44% reduction in bacterial cell viability
as compared to 18% and 31% when exposed to SDT alone and PDT alone, respectively.
For MDR. P. aeruginosa, the combined treatment resulted in a 45% reduction in bacterial
cell viability, as compared to 14% and 30% when exposed to SDT alone and PDT alone,
respectively. The killing effect was mainly due to the photodynamic and sonodynamic effects
of the nanoparticles, mainly caused by singlet oxygen. No photothermal effect was
involved in the killing.

Conclusion:
The results of this study demonstrated that IR780 iodide-loaded mesoporous
silica nanoparticles have the potential to be utilized as photo/sono therapeutic agents for
the inactivation of drug-resistant bacteria.
<i>In Vitro</i> Seed Germination and Shoot Growth of <i>Nepenthes jamban</i> Chi. C. Lee, Hernawati & Akhriadi, A Unique Pitcher Plant from Indonesia
Authors: Prawestri Apriliana Dyah , Rahayu Resa Sri , Kurniajati Wulan Septiningtyas , Sunardi Sunardi , Mansur Muhammad 
Published: June 2024

The study to optimize in vitro propagation of the Indonesian native and critically endangered species, Nepenthes jamban, in order to support the ex-situ conservation efforts has been done. Using Murashige and Skoog (MS) as a basal media, disinfected seeds of N. jamban were germinated on five types of germination media, viz. ¼ MS, ½ MS, MS, ¼ MS+benzyl adenine (BA)+Biotin and MS+BA+Biotin. Afterwards, in vitro shoots with 6-7 leaves were inoculated on growing media, i.e., ¼ MS, ¼ MS 60 (3:1) (MS modification with a higher concentration of nitrogen), and ¼ MS+naphtalene acetic acid (NAA)+BA. The results showed that the germination of N. jamban seeds was slow, indicated by the percentage of germination being less than 20% after 6 months of being planted on germination media. The highest percentage of germination was after the 6th month and the greatest pitcher development at the 10th month were obtained on ¼ MS medium. Furthermore, shoot growth and pitchers development consistently increased for 12 months in ¼ MS 60 (3:1) medium while other media resulted in a decrease in pitcher formation. It seemed that low concentrations of nutrient in the medium proved to be more effective to induce in vitro seed germination and enhance shoot growth which was also supported by higher nitrogen (nitrate) concentration in the medium. This study provides information that supports ex situ conservation action of native and critically endangered Nepenthes species from Indonesia.
1002-P: The Accuracy and Feasibility of Real-Time Continuous Glucose Monitoring in Noncritically Ill Hospitalized Patients with Type 2 Diabetes
Authors: SIRINVARAVONG SIRINART , SAKJIRAPAPONG CHOOMPUNUJ , PREECHASUK LUKANA , KUNAVISARUT TADA , WANNACHALEE TAWEESAK , THONGTANG NUNTAKORN 
Published: June 2024

Introduction: Continued use of the personal continuous glucose monitoring (CGM) device is recommended in people with diabetes who are treated with intensive insulin therapy during hospitalization to achieve better glycemic control and reduce hypoglycemia. However, initiation of the new real-time CGM (rt-CGM) in hospitalized adult patients has not been approved by the US FDA. This study aims to evaluate the accuracy and feasibility of initiating Glunovo i3 rt-CGM in hospitalized patients with type 2 diabetes mellitus who are admitted to the general medical floors.
Methods: The Glunovo i3™ rt-CGM sensor and transmitter were placed on the patient’s abdomen. The medical personnel calibrated the device with capillary blood glucose (CBG). Paired CBG and sensor glucose values were analyzed for accuracy of CGM using mean absolute relative difference (MARD) and Clarke Error Grid Analysis (CEGA).
Results: Twenty-five patients with type 2 diabetes mellitus were enrolled. Mean age was 72.8 ± 11.6 years and 64% were female. Mean HbA1c was 10±3.1%. All patients required insulin during admission. Mean duration of CGM use was 7.7±2.4 days, and the mean calibration was 2.3±0.7 times/day. There were 397 paired CBG and CGM measurements. The overall MARD was 12.2 ± 12.2%. The lowest MARD was observed in the CBG range of more than 180 mg/dL (11.0 ± 11.1%) and on day 9 of sensor wear (6.8 ± 7.1%). The percentages of glucose readings within ±15%/15 mg/dL, ±20%/20 mg/dL, and ±30%/30 mg/dL of CBG values were 72.8%, 82.9%, and 91.7%, respectively. A total of 96.7% of the data points were in zone A and B of CEGA, and none were in zone E. Percent time in range on day 1 was 41.2 ± 26.2 and improved to 48.3 ± 22.3 in the last 72 hours of sensor wear.
Conclusion: Rt-CGM use in non-critically ill hospitalized insulin-treated type 2 diabetes patients demonstrates high accuracy and potentially improves glycemic control.

Disclosure
S. Sirinvaravong: None. C. Sakjirapapong: None. L. Preechasuk: None. T. Kunavisarut: None. T. Wannachalee: None. N. Thongtang: None.

Funding
Specific League Funds, Thailand (R016421005)
1015-P: Acceptability and Impact of a Spanish-Language Diabetes Management Smartphone Application (mySugr PRO) in Hispanic/Latino Adults with Uncontrolled Type 2 Diabetes
Authors: THORSELL ASHLEY A. , BEVIER WENDY C. , CASTORINO KRISTIN N. , KERR DAVID , ULMER BRIAN , REPETTO ENRICO , GONZALEZ KARLA , MELERO LILIANA 
Published: June 2024

Hispanic/Latino (H/L) adults are disproportionately affected and have suboptimal control of Type 2 Diabetes (T2DM). We hypothesize that use of a Spanish-language smartphone application with structured blood glucose (BG) monitoring and proactive diabetes coaching (mySugr® PRO) will improve diabetes self-efficacy, weight, and glucose control in H/L adults with uncontrolled T2DM. Spanish-literate H/L adults with non-intensively treated T2DM and HbA1c 7.5-10.0% were enrolled. Subjects were provided with an Accu-Chek® Guide Me glucometer, trained on use of mySugr® PRO, received education on structured BG monitoring (paired testing before and 2hr post-meal), and given access to diabetes coaching. BG metrics, HbA1c, weight, waist circumference, diabetes self-efficacy and distress were measured before and after 12-weeks; acceptability & quality of the app were evaluated after 12 weeks. H/L adults (22) were enrolled, and 11 have completed to date. Subjects achieved significant reductions in HbA1c, weight, and waist circumference when compared to baseline. Diabetes self-efficacy and distress improved non-significantly. MySugr® PRO was well accepted and perceived to be useful by H/L adults with uncontrolled T2DM. Diabetes self-efficacy and distress improved, and the app provided them with motivation and intention to improve BG control.

Disclosure
A.A. Thorsell: None. W.C. Bevier: None. K.N. Castorino: Research Support; Abbott, Dexcom, Inc. Speaker's Bureau; Dexcom, Inc. Research Support; Lilly Diabetes, Medtronic, MannKind Corporation, Insulet Corporation. Consultant; Medscape. D. Kerr: Advisory Panel; Abbott Diagnostics. Consultant; Sanofi, Better Therapeutics, Inc. Stock/Shareholder; Glooko, Inc. B. Ulmer: Employee; Roche Diabetes Care. E. Repetto: Employee; Roche Diabetes Care. K. Gonzalez: None. L. Melero: None.
1018-P: Evaluating Continuous Glucose Monitoring Documents in Electronic Health Records—A Comparative Study of Algorithmic Classification vs. Manual Review
Authors: ZHENG YAGUANG , ITURRATE EDUARDO , LI LEHAN , WU BEI , WYLIE-ROSETT JUDITH , SMALL WILLIAM R. , ZWEIG SUSAN , FLETCHER JASON , MELKUS GAIL D. , CHEN ZHIHAO , JOHNSON STEPHEN B. 
Published: June 2024

Introduction & Objective: Clinical use of continuous glucose monitoring (CGM) is increasing collection and storage of CGM-related documents in electronic health records (EHR); however, the standardization of CGM storage is lacking. We aimed to evaluate sensitivity and specificity of CGM Ambulatory Glucose Profile (AGP) classification criteria. This work is crucial to automatically obtain AGP for real-world CGM research.
Methods: We retrieved 12,415 CGM-related documents from the EHR at NYU Langone Health 2012-2022. We randomly chose2244 (18.1%) documents to evaluate AGP classification criteria. Our document classification algorithm: 1) separated multiple-page document into a single-page image; 2) rotated all pages into an upright orientation; 3) applied optical character recognition to the image; 4) tested for the presence of particular keywords in the text. Two experts in using CGM for research and clinical practice conducted an independent manual review of 62 (2.8%) reports. We calculated sensitivity (correct classification of CGM AGP report) and specificity (correct classification of non-CGM report) by comparing the classification algorithm against manual review.
Results: Among 2244 documents, 1040 (46.5%) were classified as CGM AGP reports (43.3% FreeStyle Libre and 56.7% Dexcom), 1170 (52.1%) non-CGM reports (e.g., progress notes, CGM request forms, or physician letters), and 34 (1.5%) uncertain documents. The agreement for the evaluation of the documents between two experts were 98.4%. When comparing the classification result between the algorithm and manual review, the sensitivity and specificity were 95.0% and 91.7%.
Conclusion: Nearly half of CGM-related documents were AGP reports, which are useful for clinical practice and diabetes research; however, the remaining half documents are administrator files. Future work needs to standardize the storage of CGM-related documents in the EHR.

Disclosure
Y. Zheng: None. E. Iturrate: None. L. Li: None. B. Wu: None. J. Wylie-Rosett: None. W.R. Small: None. S. Zweig: None. J. Fletcher: None. G.D. Melkus: None. Z. Chen: None. S.B. Johnson: None.

Funding
New York Regional Center for Diabetes Translation Research (NY-CDTR); Pilot and Feasibility (P&F) award (P30DK111022-08)
1019-P: Continuous Glucose Monitoring in Pediatric Acute Lymphoblastic Leukemia
Authors: COSSEN KRISTINA , MILLER TAMARA P. , DEGROOTE NICHOLAS , STRANGE LIBERTY , STEVENSON JASON , CASTELLINO SHARON M. 
Published: June 2024

Introduction & Objective: Children with acute lymphoblastic leukemia/lymphoma (ALL/LLy) may experience significant treatment-related toxicities, graded per National Cancer Institute-prescribed definitions. During induction, development of hyperglycemia can cause significant morbidity, including monitoring, medical management, or prolonged hospitalization. An objective of the pilot study is to evaluate feasibility and efficacy of continuous glucose monitoring system (CGM) in pediatric ALL/LLy patients.
Methods: A prospective study of patients with ALL/LLy aged 1-21 years began on 2/11/2022 and is ongoing at Children’s Healthcare of Atlanta. After consent to a parent study measuring markers of hyperglycemia risk, patients are invited to enroll in a blinded CGM arm. Libre pro was utilized. Demographic and clinical data (family history of diabetes, medications, targeted AEs presence and grade) are obtained via manual chart abstraction. Descriptive statistics were calculated for study variables.
Results: As of December 2023, 53 patients completed induction in the parent study: 30 (57%) male, 35 (66%) White, 13 (35%) Black, and 42 (79%) Non-Hispanic/Latino. Diagnosis age median was 5.1 years (1.3-18.6). All patients experienced hyperglycemia: 41 (77%) grade 1; 12 (23%) grade 2+ (grade 2: n=7, 13%; grade 3: n=5, 9%). Grade 2+ hyperglycemia patients were more like to have a family history of diabetes (7/12, 53% vs. 8/41, 20%, p=0.03). Insulin management was required in grade 3 hyperglycemia. CGM was consented to and worn by 9 patients (17%) with an average CGM active time of 77% (88-92%) and 6 patients had &gt;70% wear time. During induction, 4 (44%) of the CGM arm required, compared to 1 (2%) of the non-CGM arm. CGM utilizers had no skin rash or infection at CGM site.
Conclusion: A pilot study of children with ALL/LLy showed blinded CGM technology worn during induction therapy has reliable results without complications. Additional studies are needed to explore expanded use of CGM in similar patient populations.

Disclosure
K. Cossen: None. T.P. Miller: None. N. DeGroote: None. L. Strange: None. J. Stevenson: None. S.M. Castellino: Advisory Panel; Seagen Inc, Bristol-Myers Squibb Company.

Funding
Emory/CHOA Pediatric Research Alliance (2021-00109546)
1021-P: In Silico Modeling of a Long-Term Implantable Continuous Blood Glucose Monitor—A Joint Investigation by Glucotrack Inc. and TTP
Authors: BUCKLAND JUSTIN R. , TAROTIN ILYA , MEREDITH SOPHIE A. , GOODE PAUL , THROWER JP , TAPSAK MARK A. 
Published: June 2024

Introduction & Objective: An in silico model was developed for Glucotrack's implantable Continuous Blood Glucose Monitor (CBGM). Objectives included determining the longevity of the enzyme-based, electrochemical continuous glucose sensor and identifying critical design parameters for its performance.
Methods: COMSOL Multiphysics® was used to develop an in silico model predicated on, and substantiated against, established benchmarks in continuous glucose sensor modeling research. Glucotrack sensor performance and analyte transport properties were determined from in vitro testing. The model used these inputs to simulate Glucotrack CBGM sensor longevity and performance in response to various design parameters.
Results: The Glucotrack CBGM demonstrated a simulated longevity of at least 2.5 years, as determined by the major limiting factor (enduring enzyme activity). The model enabled rapid identification of critical relationships between key sensor design parameters and the cascade of processes that occur within a glucose sensor.
Conclusion: The model provides valuable insights into implantable CBGM sensor longevity. In silico modeling, coupled with sensor properties derived from in vitro testing, is an important tool for designing successful long-term glucose sensors.

Disclosure
J.R. Buckland: Employee; TTP plc. Research Support; Glucotrack. I. Tarotin: Research Support; GlucoTrack, Inc. S.A. Meredith: Research Support; Glucotrack. Employee; TTP Plc. P. Goode: Employee; Glucotrack Inc. J. Thrower: Employee; Glucotrack Inc. M.A. Tapsak: Employee; Glucotrack Inc.
103-OR: Signaling Mechanisms Underlying Islet Compensation in a Novel Mouse Model of ß-Cell Replication Deficiency
Authors: FOSTER HANNAH R. , SDAO SOPHIA , ADAMS MELISSA , BLUM BARAK , MERRINS MATTHEW J. 
Published: June 2024

Diabetes is associated with insulin insufficiency arising from a loss of β-cell function and mass. Disinhibited glucagon secretion, arising from the loss of β-cells, is thought to be responsible for as much as half of hyperglycemia in diabetes. An alternative possibility is that increased glucagon release from α-cells is an adaptive mechanism essential to preserving β-cell function in response to the loss of β-cell mass. To study islet compensation in response to β-cell mass deficiency, we used CRISPR to generate a novel strain of β-cell replication deficient (βRD) mice (Cdk1f/f:Ucn3-Cre). We examined in vivo and ex vivo glucagon and insulin secretion in response to β-cell and α-cell stimuli, performed scRNA-seq on isolated islets, and utilized cAMP and Ca2+ biosensors to test the impact of α-cell paracrine signaling on β-cell function. In the setting of reduced β-cell mass, adult βRD mice exhibited glucose intolerance and reduced insulin secretion that was rescued by α-cell engagement with a mixed meal or intraperitoneal alanine. ScRNA-seq revealed rewiring of α-cell metabolic and secretory genes in isolated βRD islets, and glucagon secretion was increased both in vivo and ex vivo. Correspondingly, antagonism of GLP-1 and glucagon receptors resulted in defective glucose-stimulated insulin secretion in βRD islets, which was otherwise equivalent to controls, indicating that α-cell signaling is necessary to preserve β-cell function in the βRD islets. β-cell cAMP was upregulated in β-cells from βRD islets, and Ca2+ oscillations activated at lower levels of glucose than controls, suggesting that β-cell cAMP production is a key mechanism of compensation. Our results suggest that increased glucagon secretion is initially an adaptive compensation for β-cell mass deficiency. Understanding islet reprogramming under physiological and pathophysiological circumstances could accelerate development of novel therapeutics to ameliorate α and β-cell dysfunction in diabetes.

Disclosure
H.R. Foster: None. S. Sdao: None. M. Adams: Employee; Genentech, Inc. B. Blum: None. M.J. Merrins: None.

Funding
National Institutes of Health (RO1DK113103, T32AG000213, R01AG062328, R01DK127637); U.S. Department of Veterans Affairs (I01BX005113); Health Resources and Services Administration (T32HP10010)